Impact of Omission of Hyperthermic Intraperitoneal Chemotherapy for Treatment of Colorectal Peritoneal Metastases
CRS with mitomycin-HIPEC can be considered for treatment of CPM without significant morbidity and equivalent short-term oncologic benefits. However, the long-term benefit of HIPEC remains unclear.
Authors
- Anna Leung
- Kyuseok Im
- Steven Yoshinaga
Institutions
- Kaiser Permanente West Los Angeles Medical Center (US)
Publication Details
- Journal
- The Permanente Journal
- Published
- 2026-02-17
- DOI
- https://doi.org/10.7812/tpp/25.129
- Primary Topic
- Intraperitoneal and Appendiceal Malignancies
- Type
- article
- Field-Weighted Citation Impact
- 0.00